论文部分内容阅读
目的:探讨宫颈癌患者在同步放化疗中瘤体体积及其参数变化对预后的影响.方法: 回顾性分析217名接受根治性同步放化疗的宫颈癌患者.收集这些患者治疗前及外照射结束后基于核磁共振检查测得的瘤体最大径及体积,并通过随访数据分析所有患者的总生存期,疾病无进展生存期和局部无复发生存期.结果: 所有患者的5年总生存率、无进展生存率和局部无复发生存率分别为81. 3% ,85. 1%及92. 9% ,中位随访时间51个月.多因素分析显示FIGO分期在ⅢA期及以上(P=0. 029)、放疗前瘤体体积(Pre-RT TV)大于61. 6cm3 (P=0. 032)与外照射后瘤体体积( mid-RT TV)大于11. 38 cm3 ( P=0. 034)是影响总生存率的独立不良预后因素.而在单因素分析中,外照射后瘤体缩减率大于82. 19%是影响总生存率( PⅡ( P=0. 029), Pre-radiotheraPy tumor vo1ume >61. 6cm3 (P =0. 032) and mid-radiotheraPy tumor vo1ume>11. 38cm3 (P=0. 034) were significant1y associated with a worse OS. In univariate ana1ysis, tumor vo1ume reduction rate (TVRR) was significant associated with OS (P<0. 001) and LFFS ( P=0. 050). Conc1usion: TVRR and mid-radiotheraPy tumor vo1ume are va1uab1e Prognostic factors for Patients with 1oca1 advanced cervica1 cancer receiving CCRT.